Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Passes Above 200 Day Moving Average of $13.50

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $13.50 and traded as high as $14.73. Merrimack Pharmaceuticals shares last traded at $14.72, with a volume of 76,084 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Merrimack Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 31st.

Merrimack Pharmaceuticals Trading Up 0.3 %

The company’s fifty day moving average is $14.70 and its 200 day moving average is $13.50. The company has a market capitalization of $213.88 million, a P/E ratio of -184.00 and a beta of 1.43.

Merrimack Pharmaceuticals (NASDAQ:MACK) last released its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.01) EPS for the quarter.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MACK. Goldman Sachs Group Inc. purchased a new position in shares of Merrimack Pharmaceuticals during the 2nd quarter valued at $84,000. Geode Capital Management LLC grew its position in shares of Merrimack Pharmaceuticals by 33.2% during the 4th quarter. Geode Capital Management LLC now owns 134,226 shares of the biopharmaceutical company’s stock valued at $1,538,000 after purchasing an additional 33,418 shares in the last quarter. Two Sigma Investments LP grew its position in shares of Merrimack Pharmaceuticals by 97.5% during the 4th quarter. Two Sigma Investments LP now owns 42,490 shares of the biopharmaceutical company’s stock valued at $487,000 after purchasing an additional 20,971 shares in the last quarter. Boothbay Fund Management LLC purchased a new position in shares of Merrimack Pharmaceuticals during the 4th quarter valued at $736,000. Finally, Morgan Stanley grew its position in shares of Merrimack Pharmaceuticals by 40.7% during the 4th quarter. Morgan Stanley now owns 9,163 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 2,649 shares in the last quarter. 63.97% of the stock is owned by institutional investors.

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.